Traws Pharma (NASDAQ:TRAW) Coverage Initiated at HC Wainwright

Research analysts at HC Wainwright assumed coverage on shares of Traws Pharma (NASDAQ:TRAW) in a research report issued to clients and investors on Wednesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $8.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 279.15% from the company’s current price. HC Wainwright also issued estimates for Traws Pharma’s Q4 2025 earnings at ($1.91) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.54) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.56) EPS and FY2029 earnings at $0.49 EPS.

TRAW has been the topic of several other reports. Wall Street Zen raised Traws Pharma to a “hold” rating in a report on Saturday, November 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Traws Pharma in a research note on Monday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Traws Pharma currently has a consensus rating of “Hold” and an average target price of $8.00.

Traws Pharma Stock Performance

TRAW opened at $2.11 on Wednesday. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of 0.02 and a beta of 1.74. The company has a fifty day moving average of $2.39 and a 200 day moving average of $1.86. Traws Pharma has a fifty-two week low of $0.97 and a fifty-two week high of $19.44.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 2,883.04% and a net margin of 3,028.25%.

Institutional Investors Weigh In On Traws Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in TRAW. Adage Capital Partners GP L.L.C. purchased a new position in shares of Traws Pharma during the 1st quarter worth about $759,000. Vestal Point Capital LP lifted its stake in Traws Pharma by 133.3% in the first quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock worth $402,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Traws Pharma by 37.1% during the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after buying an additional 5,955 shares during the period. Hedge funds and other institutional investors own 7.95% of the company’s stock.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.